Midas Care Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.61 M
- Company Age 38 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 138.39 Cr
- Revenue Growth -14.25%
- Profit Growth -69.37%
- Ebitda -53.51%
- Net Worth 4.69%
- Total Assets 3.69%
About Midas Care Pharmaceuticals
Midas Care Pharmaceuticals Pvt Ltd (MCPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 16 May 1986 and has a history of 38 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Fmcg Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.61 M.
The company has closed loans amounting to ₹138.39 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sangithaa Brijbandhu, Shivangi Gupta, and Nandan Gupta serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239MH1986PTC039852
- Company No.
039852
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 1986
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Midas Care Pharmaceuticals Pvt Ltd offer?
Midas Care Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream, Pain Relief Drugs & Pharmaceuticals, Pain Relief Spray.
Who are the key members and board of directors at Midas Care Pharmaceuticals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Sangithaa Brijbandhu ![]() | Managing Director | 15-Sep-1986 | Current |
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Shivangi Gupta ![]() | Director | 21-Oct-2005 | Current |
Nandan Gupta ![]() | Director | 01-Mar-2011 | Current |
Financial Performance of Midas Care Pharmaceuticals.
Midas Care Pharmaceuticals Pvt Ltd, for the financial year ended 2024, experienced significant reduction in revenue, with a 14.25% decrease. The company also saw a substantial fall in profitability, with a 69.37% decrease in profit. The company's net worth moved up by a moderate rise of 4.69%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Midas Care Pharmaceuticals?
In 2024, Midas Care Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹0
₹1,383.91 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 119.60 Cr
- Icici Bank Limited : 14.50 Cr
- Deutsche Bank Ag : 2.50 Cr
- Bank Of Baroda : 1.73 Cr
- The Saraswat Co Op Bank Of Ltd : 0.04 Cr
- Others : 0.03 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
29 Sep 2017 | Hdfc Bank Limited | ₹7.30 Cr | Satisfied |
18 Sep 2013 | Icici Bank Limited | ₹14.50 Cr | Satisfied |
28 Nov 2011 | Deutsche Bank Ag | ₹2.50 Cr | Satisfied |
16 Oct 2008 | Hdfc Bank Limited | ₹50.25 Cr | Satisfied |
24 Jul 2007 | Hdfc Bank Limited | ₹62.05 Cr | Satisfied |
How Many Employees Work at Midas Care Pharmaceuticals?
Midas Care Pharmaceuticals has a workforce of 413 employees as of Feb 19, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Midas Care Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Midas Care Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.